Bachman E A, Senapati S, Sammel M D, Kalra S K
University of Pennsylvania, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, 3701 Market Street, Suite 800, Philadelphia, PA 19104, United States.
University of Pennsylvania, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, 3701 Market Street, Suite 800, Philadelphia, PA 19104, United States.
Reprod Biomed Online. 2014 Jun;28(6):748-52. doi: 10.1016/j.rbmo.2014.02.012. Epub 2014 Mar 4.
Many women experience pain during hysterosalpingogram (HSG). This prospective, randomized, double-blinded, placebo-controlled study assessed whether the use of benzocaine spray during HSG is associated with reduced pain as compared with placebo. Thirty women presenting for HSG were enrolled and randomized to either benzocaine or saline spray. Treatment groups were similar in age, race, parity, pre-procedure oral analgesic use and history of dysmenorrhoea and/or chronic pelvic pain. Median change in pain score from baseline to procedure was 50.6mm (-7.4 to 98.8mm) in the benzocaine group and 70.4mm (19.8 to 100mm) in the placebo group. There was no difference between groups after adjusting for history of dysmenorrhoea. There was no difference in resolution of pain in benzocaine versus placebo groups at 5 min post procedure--median pain score difference -11.1 (-90.1 to 18.5) versus -37.0 (-100 to 1.2)--or at 30 min post procedure. Satisfaction scores did not differ by treatment and did not correlate with pain score during the procedure (rho=0.005). The use of benzocaine spray does not significantly improve pain relief during HSG nor does it hasten resolution of pain post HSG. Of interest, patient satisfaction was not correlated with pain. Many women experience pain during hysterosalpingogram (HSG), which is a test used to evaluate the uterine cavity and fallopian tube. We conducted a prospective, randomized, double-blinded, placebo-controlled study to assess whether the use of benzocaine spray during HSG is associated with reduced pain as compared with placebo. Thirty women presenting for HSG were enrolled and randomized to either benzocaine or saline spray. Treatment groups were similar in age, race, previous pregnancies, pre-procedure oral analgesic use and history of dysmenorrhoea (painful periods) and/or chronic pelvic pain. There was no difference in pain scores or resolution of pain between the two groups. Satisfaction scores did not differ by treatment group and did not correlate with the pain score during the procedure. We conclude that the use of benzocaine spray does not significantly improve pain relief during HSG nor does it hasten resolution of pain post HSG. Of interest, patient satisfaction was not correlated with pain.
许多女性在子宫输卵管造影术（HSG）过程中会经历疼痛。这项前瞻性、随机、双盲、安慰剂对照研究评估了在HSG过程中使用苯佐卡因喷雾剂与使用安慰剂相比，是否能减轻疼痛。30名前来接受HSG检查的女性被纳入研究，并随机分为苯佐卡因组或生理盐水喷雾组。治疗组在年龄、种族、产次、术前口服镇痛药的使用以及痛经和/或慢性盆腔疼痛病史方面相似。苯佐卡因组从基线到检查过程中疼痛评分的中位数变化为50.6mm（-7.4至98.8mm），安慰剂组为70.4mm（19.8至100mm）。在调整痛经病史后，两组之间没有差异。在检查后5分钟，苯佐卡因组和安慰剂组的疼痛缓解情况没有差异——疼痛评分中位数差异为-11.1（-90.1至18.5）与-37.0（-100至1.2）——在检查后30分钟时也没有差异。满意度评分在不同治疗组之间没有差异，并且与检查过程中的疼痛评分无关（相关系数rho=0.005）。使用苯佐卡因喷雾剂并不能显著改善HSG过程中的疼痛缓解情况，也不能加速HSG后疼痛的缓解。有趣的是，患者满意度与疼痛无关。许多女性在子宫输卵管造影术（HSG）过程中会经历疼痛，这是一种用于评估子宫腔和输卵管的检查。我们进行了一项前瞻性、随机、双盲、安慰剂对照研究，以评估在HSG过程中使用苯佐卡因喷雾剂与使用安慰剂相比，是否能减轻疼痛。30名前来接受HSG检查的女性被纳入研究，并随机分为苯佐卡因组或生理盐水喷雾组。治疗组在年龄、种族、既往妊娠情况、术前口服镇痛药的使用以及痛经（经期疼痛）和/或慢性盆腔疼痛病史方面相似。两组在疼痛评分或疼痛缓解方面没有差异。满意度评分在不同治疗组之间没有差异，并且与检查过程中的疼痛评分无关。我们得出结论，使用苯佐卡因喷雾剂并不能显著改善HSG过程中的疼痛缓解情况，也不能加速HSG后疼痛的缓解。有趣的是，患者满意度与疼痛无关。
